Citius Pharmaceuticals, Inc. (CTXR) financial statements (2022 and earlier)

Company profile

Business Address 11 COMMERCE DRIVE
CRANFORD, NJ 07016
State of Incorp. NV
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q1
9/30/2021
Q4
6/30/2021
Q3
3/31/2021
Q2
12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments65,42170,073115,664103,6974,29613,8608,517
Cash and cash equivalents65,42170,073115,664103,6974,29613,8608,517
Prepaid expense2,5242,7411,2711,2771,28312252
Total current assets:67,94572,814116,935104,9745,57913,9828,569
Noncurrent Assets
Operating lease, right-of-use asset7808238659069479861,025
Leveraged leases, net investment in leveraged leases disclosure, investment in leveraged leases      1,025
Property, plant and equipment6781122
Intangible assets, net (including goodwill)9,3479,3479,3479,3479,3479,3479,347
Goodwill9,3479,3479,3479,3479,3479,3479,347
Other undisclosed noncurrent assets59,43859,43819,43819,43819,43819,45718,432
Total noncurrent assets:69,57169,61529,65729,69229,73329,79229,831
TOTAL ASSETS:137,516142,429146,593134,66635,31243,77438,400
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,1603,8053,2632,6443,2113,7653,282
Accounts payable1,7891,2771,3551,1339841,8561,812
Accrued liabilities3,137622367241252164164
Employee-related liabilities2,2341,9061,5401,1721,8811,6551,220
Interest and dividends payable  298949087
Debt   173173173173
Other undisclosed current liabilities182177337168163159155
Total current liabilities:7,3423,9823,6002,9853,5484,0973,610
Noncurrent Liabilities
Long-term debt and lease obligation6316787259349771,0201,062
Long-term debt, excluding current maturities   165165165165
Operating lease, liability631678725769813855897
Liabilities, other than long-term debt4,9864,9864,9864,9864,9864,9864,986
Deferred income tax liabilities4,9864,9864,9864,9864,9864,9864,986
Total noncurrent liabilities:5,6175,6645,7115,9205,9636,0066,048
Total liabilities:12,9589,6469,3118,9049,51110,1039,658
Stockholders' equity
Stockholders' equity attributable to parent123,958132,182136,682125,16225,20033,67128,742
Common stock146146146135565646
Additional paid in capital229,085228,084227,622210,290106,285104,20995,169
Accumulated deficit(105,273)(96,048)(91,087)(85,263)(81,140)(70,594)(66,473)
Stockholders' equity attributable to noncontrolling interest600600600600600  
Total stockholders' equity:124,558132,783137,282125,76225,80133,67128,742
TOTAL LIABILITIES AND EQUITY:137,516142,429146,593134,66635,31243,77438,400

Income statement (P&L) ($ in thousands)

12/31/2021
Q1
9/30/2021
Q4
6/30/2021
Q3
3/31/2021
Q2
12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
Revenues  90    
Other income  60    
Gross profit:  90    
Operating expenses(9,259)(5,203)(5,984)(4,188)(8,156)(4,141)(4,689)
Other undisclosed operating loss (90)(90)    
Operating loss:(9,259)(5,293)(5,984)(4,188)(8,156)(4,141)(4,689)
Nonoperating income342421606510209
Investment income, nonoperating347610369132413
Interest and debt expense 333(0)(4)(4)(3)(4)
Loss from continuing operations before equity method investments, income taxes:(9,225)(4,718)(5,824)(4,126)(8,151)(4,124)(4,684)
Income from equity method investments    110  
Other undisclosed income from continuing operations before income taxes     16 
Loss from continuing operations before income taxes:(9,225)(4,718)(5,824)(4,126)(8,041)(4,108)(4,684)
Income tax expense (1)(0)(0)(0)  
Loss before gain (loss) on sale of properties:(9,225)(4,719)(5,825)(4,127)(8,041)(4,108)(4,684)
Other undisclosed net income (loss) (321)14(106) 4
Net loss:(9,225)(5,040)(5,824)(4,122)(8,147)(4,108)(4,680)
Other undisclosed net income (loss) attributable to parent 79   (12) 
Net loss attributable to parent:(9,225)(4,961)(5,824)(4,122)(8,147)(4,121)(4,680)
Preferred stock dividends and other adjustments  (1,451)    
Net loss available to common stockholders, diluted:(9,225)(4,961)(7,275)(4,122)(8,147)(4,121)(4,680)

Comprehensive Income ($ in thousands)

12/31/2021
Q1
9/30/2021
Q4
6/30/2021
Q3
3/31/2021
Q2
12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
Net loss:(9,225)(5,040)(5,824)(4,122)(8,147)(4,108)(4,680)
Comprehensive loss, net of tax, attributable to parent:(9,225)(5,040)(5,824)(4,122)(8,147)(4,108)(4,680)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: